# Eltrombopag Combined With Cyclosporine as First Line Therapy in Patients With Severe Acquired Aplastic Anemia

> **NCT02998645** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 54 (actual)

## Conditions studied

- Severe Aplastic Anemia

## Interventions

- **DRUG:** eltrombopag
- **DRUG:** Cyclosporine

## Key facts

- **NCT ID:** NCT02998645
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-11
- **Primary completion:** 2020-11-03
- **Final completion:** 2022-05-30
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2023-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02998645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02998645, "Eltrombopag Combined With Cyclosporine as First Line Therapy in Patients With Severe Acquired Aplastic Anemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02998645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*